The US Oncology Network in The News

Expansive clinical research and real-world evidence data to be presented on prostate cancer, genome sequencing, melanoma, bladder cancer, metastatic breast cancer and more

The Woodlands, Texas (May 30, 2018) – McKesson Specialty Health announced today that oncologists from The US Oncology Network (The Network) and US Oncology Research will showcase detailed findings from 43 studies during the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO), held June 1–5, 2018, in Chicago with more than 32,000 oncology professionals in attendance. The study abstracts accepted for presentation represent substantial contributions made by community oncologists towards the understanding and advancement of cancer care.

“Research conducted by community oncologists and presented at this year’s ASCO meeting demonstrates the dedication of these professionals in not only advancing investigational treatment options, but also offering cutting-edge research to their patients,” said Michael Seiden, M.D., Ph.D., president and chief medical officer for The US Oncology Network and US Oncology Research. “There have been tremendous advancements in cancer care, and being selected for a clinical study is no longer seen as a last option, but rather as access to some of the latest investigational therapies for treating a wide range of cancers. Our community-based oncology network, made up of 1,400 independent physicians, allows access to resources and emerging treatments across the country. This meeting provides a time to focus on the unmet needs of patients through clinical trials that are leading the way in the fight against cancer.”

Key study presentations will include topics such as genome sequencing in lung cancer, metastatic breast cancer, real-world evidence in bladder cancer and melanoma, and Phase 3 data from the PROTECT study in asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer.

“The ability for community oncologists to participate in groundbreaking cancer research must remain a high priority for all research organizations, including those programs supported by the National Cancer Institute,” said Nicholas J. Vogelzang, M.D., FASCO, FACP, medical oncologist with Comprehensive Cancer Centers of Nevada, an affiliate of The US Oncology Network, and 2018 recipient of an OncLive Giants of Cancer Care award. “It is critically important for oncologists around the world, regardless of the type of center they are practicing in, to be able to find time to conduct research and make advancements in cancer care. I’m proud to be an active clinical investigator within The US Oncology Network, where several studies have been selected for presentation at this year’s ASCO annual meeting. This conference is a time for us to share knowledge and gain insights to better and more effectively treat patients, while contributing to our collective mission to eradicate cancer.”

Key oral presentations will include:

• Results of PROTECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer
  Abstract #: 5006
  Date/Time: Monday, June 4, 3-6:00 p.m.
  Location: Hall D1
  Affiliated Author: Nicholas J. Vogelzang, M.D., FASCO, FACP, Comprehensive Cancer Centers of Nevada, US Oncology Research
   
• Genome-wide sequencing for early stage lung cancer detection from plasma cell-free DNA (cfDNA): The Circulating Cancer Genome Atlas (CCGA) studyAbstract #: LBA8501
  Date/Time: Monday, June 4, 8-11:00 a.m.
  Location: Hall B1
  Affiliated Author: Donald Richards, M.D., Ph.D., Texas Oncology, The US Oncology Network
   
• Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (mBC)
  Abstract #: 1004
  Date/Time: Sunday, June 3, 8-11:00 a.m.
  Location: Hall D2
  Affiliated Author: Joyce O’Shaughnessy, M.D., Texas Oncology, The US Oncology Network, US Oncology Research
   
• First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt)
  Abstract #: 4503
  Date/Time: Sunday, June 3, 8–-11:00 a.m.
  Location: Arie Crown Theater
  Affiliated Author: Mark T. Fleming, M.D., Virginia Oncology Associates, US Oncology Research
   
• Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: Exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study
  Abstract #: 12003
  Date/Time: Tuesday, June 5, 8–11:00 a.m.
  Location: S406
  Affiliated Author: Michael Seiden, M.D., Ph.D., The US Oncology Network, US Oncology Research

An additional 29 poster presentations and nine published abstracts affiliated with US Oncology Research will be featured as part of the ASCO program. The full schedule of US Oncology Research–affiliated data presentations, including location information, can be found here.

For more information or to be put in touch with a trial investigator, please contact Edie DeVine at 209-814-9564 or Edie.DeVine@gcihealth.com. Please visit Booth #5123 on the Main Floor at ASCO.

About US Oncology Research

Supported by McKesson Specialty Health and The US Oncology Network, US Oncology Research draws from a network of experienced investigators and dedicated clinical staff who specialize in oncology clinical trials. US Oncology Research serves approximately 60 research sites and nearly 160 locations managing about 300 active trials at any given time. Physicians in the research network have enrolled more than 73,000 patients in more than 1,600 trials since inception in 1992 and have played a role in more than 70 FDA-approved cancer therapies, about one-third of all cancer therapies approved by the FDA to date. For more information call 800-482-6700 or visit www.usoncology.com/oncologists.

About The US Oncology Network

The US Oncology Network is one of the nation’s largest networks of integrated, community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care. A physician-led organization, The US Oncology Network unites like-minded physicians and clinicians around a common vision of improving patient outcomes and quality of life. Leveraging healthcare information technology, shared best practices, evidence-based guidelines and quality measurements, physicians within The US Oncology Network are pioneering new ways to achieve this vision. The US Oncology Network is committed to strengthening patient access to integrated care in local communities across the nation, including collaboration with a variety of payers, hospitals and academic institutions. The US Oncology Network is supported by McKesson Specialty Health, a division of McKesson Corporation focused on empowering a vibrant and sustainable community patient care delivery system. For more information, visit www.usoncology.com.

About McKesson Specialty Health

McKesson Specialty Health, a division of McKesson Corporation, works together with stakeholders across the healthcare delivery system to preserve and strengthen specialty care, passionately driven by the benefits it provides patients and the system as a whole. Through innovative provider, practice management, biopharma and payer solutions, McKesson Specialty Health focuses on improving the financial, operational and business health of our customers and partners so they may provide the best care to patients. At McKesson Specialty Health, we believe that we are all in this together. For more information, visit www.mckessonspecialtyhealth.com.

Media Contact

Edie DeVine
GCI Health
209-814-9564
Edie.DeVine@gcihealth.com

###